FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106554920> ?p ?o ?g. }

• W3106554920 abstract "Abstract Background The bleeding risk profile of patients with atrial fibrillation (AF) may change over time and the increment of HAS-BLED score (a validated bleeding risk score) is perceived to result in discontinuations of oral anticoagulants (OACs). The goal of the present study was to investigate the changes of HAS-BLED scores of AF patients initially with a low bleeding risk (HAS-BLED 0–2). Second, the impact of continuation or discontinuation of OACs on clinical outcomes after patients' bleeding risk profile worsened (ie HAS-BLED increased) were also studied. Methods The present study used the Taiwan nationwide health insurance research (NHIRD) database. From year 2000 to 2015, a total of 24,990 AF patients aged &gt;20 years with a CHA2DS2-VASc score &gt;1 (males) or &gt;2 (females) having a HAS-BLED score of 0–2 who were treated with OACs (warfarin or NOACs) were identified and followed up for changes of the HAS-BLED scores. The risks of clinical outcomes were compared between patients who continued or stopped OAC's once their HAS-BLED score increased to ≥3. Results Mean HAS-BLED score of study population continuously increased from 1.54 (SD 1.63) at baseline, to 3.33 (SD 1.36) at the end of follow up with increasing age and incident comorbidities (Figure A). At end of 1 year, 5,229 (20.9%) patients had an increment of their HAS-BLED score to ≥3, mainly due to newly diagnosed impaired renal function, occurrences of bleeding events and concurrent use of antiplatelet agents or NSAIDs. Among 4,777 patients who consistently had a HAS-BLED score &gt; =3, 1,062 (22.2%) stopped their use of OACs. Patients who kept on OACs (n=3,715; 77.8%) even after their HAS-BLED score increased to ≥3 were associated with a lower risk of ischemic stroke (aHR 0.601), major bleeding (aHR 0.780), all-cause mortality (aHR 0.876) and any adverse events (aHR 0.748) (Figure B). Conclusions For patients whose HAS-BLED scores increased to ≥3, the continuation of OACs (which occurred in the majority of patients) was associated with better clinical outcomes. An increased HAS-BLED score in AF patients is not a reason to withhold OACs, but reminds physicians to correct modifiable bleeding risk factors and follow up patients more closely. The low risk of bleeding despite continuing OAC in high HAS-BLED score patients may reflect the early reviews and careful follow-up of these “high risk” patients (as recommended in guidelines). Funding Acknowledgement Type of funding source: None" @default.
• W3106554920 created "2020-12-07" @default.
• W3106554920 creator A5050407708 @default.
• W3106554920 creator A5055177523 @default.
• W3106554920 creator A5062584809 @default.
• W3106554920 creator A5083368276 @default.
• W3106554920 date "2020-11-01" @default.
• W3106554920 modified "2023-09-26" @default.
• W3106554920 title "Continuation or discontinuation of oral anticoagulants after an increase in HAS-BLED scores and the risks of clinical outcomes in patients with atrial fibrillation. a nationwide cohort study" @default.
• W3106554920 doi "https://doi.org/10.1093/ehjci/ehaa946.0638" @default.
• W3106554920 hasPublicationYear "2020" @default.
• W3106554920 type Work @default.
• W3106554920 sameAs 3106554920 @default.
• W3106554920 citedByCount "0" @default.
• W3106554920 crossrefType "journal-article" @default.
• W3106554920 hasAuthorship W3106554920A5050407708 @default.
• W3106554920 hasAuthorship W3106554920A5055177523 @default.
• W3106554920 hasAuthorship W3106554920A5062584809 @default.
• W3106554920 hasAuthorship W3106554920A5083368276 @default.
• W3106554920 hasBestOaLocation W31065549201 @default.
• W3106554920 hasConcept C126322002 @default.
• W3106554920 hasConcept C201903717 @default.
• W3106554920 hasConcept C2776301958 @default.
• W3106554920 hasConcept C2778715236 @default.
• W3106554920 hasConcept C2779161974 @default.
• W3106554920 hasConcept C2908647359 @default.
• W3106554920 hasConcept C71924100 @default.
• W3106554920 hasConcept C72563966 @default.
• W3106554920 hasConcept C99454951 @default.
• W3106554920 hasConceptScore W3106554920C126322002 @default.
• W3106554920 hasConceptScore W3106554920C201903717 @default.
• W3106554920 hasConceptScore W3106554920C2776301958 @default.
• W3106554920 hasConceptScore W3106554920C2778715236 @default.
• W3106554920 hasConceptScore W3106554920C2779161974 @default.
• W3106554920 hasConceptScore W3106554920C2908647359 @default.
• W3106554920 hasConceptScore W3106554920C71924100 @default.
• W3106554920 hasConceptScore W3106554920C72563966 @default.
• W3106554920 hasConceptScore W3106554920C99454951 @default.
• W3106554920 hasLocation W31065549201 @default.
• W3106554920 hasOpenAccess W3106554920 @default.
• W3106554920 hasPrimaryLocation W31065549201 @default.
• W3106554920 hasRelatedWork W11502963 @default.
• W3106554920 hasRelatedWork W11633418 @default.
• W3106554920 hasRelatedWork W15234745 @default.
• W3106554920 hasRelatedWork W15492122 @default.
• W3106554920 hasRelatedWork W17574056 @default.
• W3106554920 hasRelatedWork W5832825 @default.
• W3106554920 hasRelatedWork W6668650 @default.
• W3106554920 hasRelatedWork W12952029 @default.
• W3106554920 hasRelatedWork W1651283 @default.
• W3106554920 hasRelatedWork W18000870 @default.
• W3106554920 isParatext "false" @default.
• W3106554920 isRetracted "false" @default.
• W3106554920 magId "3106554920" @default.
• W3106554920 workType "article" @default.